File Download

There are no files associated with this item.

Supplementary

Conference Paper: Psychotropic medicine consumption in 83 countries and regions between 2017 and 2022

TitlePsychotropic medicine consumption in 83 countries and regions between 2017 and 2022
Authors
Huang, CaigeWei, YueYan, Vincent Ka ChunChan, Esther Wai Yin
Issue Date13-Oct-2024
Abstract

Introduction:
There have been concerns about the potential impacts of the COVID-19 pandemic on mental health
conditions since the pandemic, but global studies on this topic remain limited. The global monitoring
of country-level psychotropic medication consumption trends can provide information on the
availability and utilisation of psychotropic medications during the pandemic.
Aims:
To investigate trends in psychotropic medication consumption from 2017 to 2022 across 83 high- and
middle-income countries according to country income level.
Methods:
We used quarterly pharmaceutical sales data of psychotropic medications from the IQVIAMultinational
Integrated Data Analysis System (IQVIA-MIDAS). Total psychotropic consumption
included sales of antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants. Average
annual sales trends of psychotropic medications were expressed as defined daily dose (DDD) per
1000 inhabitants per day. Compound annual growth rate (CAGR) was used to assess changes in
consumption over time.
Results:
Psychotropic medication sales rose from 30.19 to 35.10 DDD per 1000 inhabitants per day from 2017
to 2022 (CAGR 3.06%). From 2017 to 2022, consumption of antipsychotics and antidepressants
increased at a CAGR of 2.72% and 5.23%, respectively, while consumption of anxiolytics, hypnotics
and sedatives decreased at a CAGR of -0.55% and -0.27%, respectively. From 2019 to 2020,
anxiolytics (CAGR 3.04%), hypnotics and sedatives (CAGR 2.18%) observed a significant increase, but
their consumption decreased from 2021 to 2022. High-income countries experienced the largest
growth in consumption of psychotropic medications.
Discussion:
The overall consumption of psychotropic medications in 83 high- and middle-income countries has
increased from 2017 to 2022, with the highest growth observed in antidepressants and high-income
countries. The observed increase in consumption of anxiolytics, hypnotics and sedatives during the
pandemic, followed by a decrease after the pandemic, indicates that there were increased anxiety
and sleep difficulties during the pandemic and it's possible that these issues naturally improve after
the pandemic.


Persistent Identifierhttp://hdl.handle.net/10722/355215

 

DC FieldValueLanguage
dc.contributor.authorHuang, Caige-
dc.contributor.authorWei, Yue-
dc.contributor.authorYan, Vincent Ka Chun-
dc.contributor.authorChan, Esther Wai Yin-
dc.date.accessioned2025-03-29T00:35:21Z-
dc.date.available2025-03-29T00:35:21Z-
dc.date.issued2024-10-13-
dc.identifier.urihttp://hdl.handle.net/10722/355215-
dc.description.abstract<p>Introduction:<br>There have been concerns about the potential impacts of the COVID-19 pandemic on mental health<br>conditions since the pandemic, but global studies on this topic remain limited. The global monitoring<br>of country-level psychotropic medication consumption trends can provide information on the<br>availability and utilisation of psychotropic medications during the pandemic.<br>Aims:<br>To investigate trends in psychotropic medication consumption from 2017 to 2022 across 83 high- and<br>middle-income countries according to country income level.<br>Methods:<br>We used quarterly pharmaceutical sales data of psychotropic medications from the IQVIAMultinational<br>Integrated Data Analysis System (IQVIA-MIDAS). Total psychotropic consumption<br>included sales of antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants. Average<br>annual sales trends of psychotropic medications were expressed as defined daily dose (DDD) per<br>1000 inhabitants per day. Compound annual growth rate (CAGR) was used to assess changes in<br>consumption over time.<br>Results:<br>Psychotropic medication sales rose from 30.19 to 35.10 DDD per 1000 inhabitants per day from 2017<br>to 2022 (CAGR 3.06%). From 2017 to 2022, consumption of antipsychotics and antidepressants<br>increased at a CAGR of 2.72% and 5.23%, respectively, while consumption of anxiolytics, hypnotics<br>and sedatives decreased at a CAGR of -0.55% and -0.27%, respectively. From 2019 to 2020,<br>anxiolytics (CAGR 3.04%), hypnotics and sedatives (CAGR 2.18%) observed a significant increase, but<br>their consumption decreased from 2021 to 2022. High-income countries experienced the largest<br>growth in consumption of psychotropic medications.<br>Discussion:<br>The overall consumption of psychotropic medications in 83 high- and middle-income countries has<br>increased from 2017 to 2022, with the highest growth observed in antidepressants and high-income<br>countries. The observed increase in consumption of anxiolytics, hypnotics and sedatives during the<br>pandemic, followed by a decrease after the pandemic, indicates that there were increased anxiety<br>and sleep difficulties during the pandemic and it's possible that these issues naturally improve after<br>the pandemic.</p>-
dc.languageeng-
dc.relation.ispartof16th Asian Conference on Pharmacoepidemiology (12/10/2024-14/10/2024, Tokyo)-
dc.titlePsychotropic medicine consumption in 83 countries and regions between 2017 and 2022-
dc.typeConference_Paper-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats